Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Pfizer, Medivation Halt Alzheimer’s Pact
by Lisa M. Jarvis
January 23, 2012
| A version of this story appeared in
Volume 90, Issue 4
Pfizer and Medivation are ending their collaboration for the Alzheimer’s disease drug candidate dimebon and discontinuing development of the compound. The news comes after a Phase III study showed that giving the drug in combination with Pfizer’s Aricept did not improve cognitive ability or daily functioning in people with Alzheimer’s disease. In 2008, Pfizer paid $225 million for access to dimebon and agreed to pay Medivation upward of $500 million as the drug candidate progressed. The big pharma firm also took on 60% of the development expenses for the failed drug.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X